ZA201508213B - 3,4-dihydroisoquinolin-2(1h)-yl compounds - Google Patents

3,4-dihydroisoquinolin-2(1h)-yl compounds

Info

Publication number
ZA201508213B
ZA201508213B ZA2015/08213A ZA201508213A ZA201508213B ZA 201508213 B ZA201508213 B ZA 201508213B ZA 2015/08213 A ZA2015/08213 A ZA 2015/08213A ZA 201508213 A ZA201508213 A ZA 201508213A ZA 201508213 B ZA201508213 B ZA 201508213B
Authority
ZA
South Africa
Prior art keywords
dihydroisoquinolin
compounds
Prior art date
Application number
ZA2015/08213A
Other languages
English (en)
Inventor
Craig Daniel Wolfangel
John Mehnert Schaus
Matthew Robert Reinhard
Jr Joseph Herman Krushinski
Junliang Hao
David Andrew Coates
Christopher David Beadle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA201508213B publication Critical patent/ZA201508213B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA2015/08213A 2013-05-30 2015-11-06 3,4-dihydroisoquinolin-2(1h)-yl compounds ZA201508213B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361828740P 2013-05-30 2013-05-30
US201361905329P 2013-11-18 2013-11-18
PCT/US2014/039494 WO2014193781A1 (en) 2013-05-30 2014-05-27 3,4-dihydroisoquinolin-2(1h)-yl compounds

Publications (1)

Publication Number Publication Date
ZA201508213B true ZA201508213B (en) 2017-08-30

Family

ID=50983199

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/08213A ZA201508213B (en) 2013-05-30 2015-11-06 3,4-dihydroisoquinolin-2(1h)-yl compounds

Country Status (38)

Country Link
US (1) US8962654B2 (es)
EP (1) EP3004061B8 (es)
JP (2) JP6130590B2 (es)
KR (1) KR101808933B1 (es)
CN (1) CN105228985B (es)
AP (1) AP2015008867A0 (es)
AU (2) AU2014274435B2 (es)
BR (1) BR112015029090B1 (es)
CA (1) CA2912849C (es)
CL (1) CL2015003444A1 (es)
CR (1) CR20150622A (es)
CY (1) CY1119361T1 (es)
DK (1) DK3004061T3 (es)
DO (1) DOP2015000289A (es)
EA (1) EA029220B1 (es)
ES (1) ES2647086T3 (es)
GT (1) GT201500334A (es)
HK (1) HK1216314A1 (es)
HR (1) HRP20171696T1 (es)
HU (1) HUE034607T2 (es)
JO (1) JO3316B1 (es)
LT (1) LT3004061T (es)
ME (1) ME02838B (es)
MX (1) MX2015016495A (es)
MY (1) MY180751A (es)
NZ (1) NZ713809A (es)
PE (1) PE20152032A1 (es)
PH (1) PH12015502658B1 (es)
PL (1) PL3004061T3 (es)
PT (1) PT3004061T (es)
RS (1) RS56294B1 (es)
SG (1) SG11201509310QA (es)
SI (1) SI3004061T1 (es)
TN (1) TN2015000514A1 (es)
TW (2) TWI691489B (es)
UA (1) UA118759C2 (es)
WO (1) WO2014193781A1 (es)
ZA (1) ZA201508213B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010324810B2 (en) 2009-11-27 2016-05-12 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
AR106332A1 (es) * 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
CA3018352A1 (en) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
AU2018225556A1 (en) 2017-02-21 2019-10-03 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
EP3418270A1 (en) 2017-06-19 2018-12-26 Universidad Complutense De Madrid Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
EP3717025B1 (en) 2017-12-01 2021-11-03 UCB Biopharma SRL Imaging agents
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
AU2019402087B2 (en) 2018-12-18 2023-04-06 Eli Lilly And Company Dose regimens for use of LY3154207 in the treatment of dopaminergic CNS disorders
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
WO2021001286A1 (en) 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2021015873A (es) 2019-07-01 2022-02-03 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.
WO2022076418A1 (en) 2020-10-07 2022-04-14 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
CN116507332A (zh) 2020-12-03 2023-07-28 Ucb生物制药有限责任公司 八氢异喹啉基衍生物
MX2023007155A (es) 2020-12-18 2023-06-28 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como un modulador alosterico positivo de d1.
US20240083875A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Dihydroisoquinolinyl derivatives
IL303688A (en) * 2020-12-18 2023-08-01 UCB Biopharma SRL Amorphous solid dispersions
US20240083925A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
BR112023018175A2 (pt) 2021-03-08 2023-10-31 Lilly Co Eli Uso de mevidalen e outros moduladores alostéricos d1 positivos no tratamento de alucinações e psicose relacionada à demência
WO2022192255A1 (en) 2021-03-09 2022-09-15 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE97893T1 (de) 1988-02-19 1993-12-15 Smithkline Beecham Farma 1,2,3,4-tetrahydroisoquinoline, verfharen zu ihrer herstellung und ihre verwendung als kappa- rezeptor agonisten.
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
US20090099158A1 (en) 2007-03-01 2009-04-16 Grice Cheryl A Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
KR20140107550A (ko) 2011-12-21 2014-09-04 액테리온 파마슈티칼 리미티드 헤테로시클릴 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 그의 용도
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
US20140357664A1 (en) 2014-12-04
MY180751A (en) 2020-12-08
BR112015029090A2 (pt) 2017-07-25
KR20160003110A (ko) 2016-01-08
NZ713809A (en) 2019-11-29
CN105228985A (zh) 2016-01-06
TWI691488B (zh) 2020-04-21
MX2015016495A (es) 2016-03-01
CR20150622A (es) 2016-01-06
BR112015029090A8 (pt) 2020-03-17
US8962654B2 (en) 2015-02-24
CY1119361T1 (el) 2018-02-14
CA2912849A1 (en) 2014-12-04
AU2016238934A1 (en) 2016-10-27
DK3004061T3 (en) 2017-10-23
ME02838B (me) 2018-01-20
PL3004061T3 (pl) 2018-01-31
UA118759C2 (uk) 2019-03-11
PH12015502658A1 (en) 2016-03-07
JP6130590B2 (ja) 2017-05-17
KR101808933B1 (ko) 2017-12-13
TW201536745A (zh) 2015-10-01
PT3004061T (pt) 2017-10-19
SG11201509310QA (en) 2015-12-30
EA201592082A1 (ru) 2016-04-29
HRP20171696T1 (hr) 2017-12-29
SI3004061T1 (sl) 2017-10-30
EA029220B1 (ru) 2018-02-28
EP3004061B8 (en) 2017-10-04
HUE034607T2 (en) 2018-02-28
CN105228985B (zh) 2017-05-10
TW201940469A (zh) 2019-10-16
AU2016238934B2 (en) 2017-08-03
JP2016520127A (ja) 2016-07-11
LT3004061T (lt) 2017-11-27
PH12015502658B1 (en) 2016-03-07
CA2912849C (en) 2017-05-30
EP3004061A1 (en) 2016-04-13
JP6387433B2 (ja) 2018-09-05
TN2015000514A1 (en) 2017-04-06
CL2015003444A1 (es) 2016-07-15
AU2014274435B2 (en) 2016-07-14
BR112015029090B1 (pt) 2023-05-09
JP2017178945A (ja) 2017-10-05
AU2014274435A1 (en) 2015-11-19
DOP2015000289A (es) 2015-12-31
PE20152032A1 (es) 2016-01-28
TWI691489B (zh) 2020-04-21
WO2014193781A1 (en) 2014-12-04
JO3316B1 (ar) 2019-03-13
EP3004061B1 (en) 2017-08-30
ES2647086T3 (es) 2017-12-19
GT201500334A (es) 2018-11-23
RS56294B1 (sr) 2017-12-29
HK1216314A1 (zh) 2016-11-04
AP2015008867A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
HK1216314A1 (zh) -二氫異喹啉- -基化合物
ZA201905393B (en) Selectively substituted quinoline compounds
IL267031B (en) Selectively converted quinoline compounds
GB201303109D0 (en) Novel pyrimidine compounds
IL245704A0 (en) ccr6 compounds
SI2970339T1 (sl) 1-hidroksi-benzooksaboroli kot sredstva proti parazitom
HK1207317A1 (en) Substituted 1,6-naphthyridines 16-
GB201300632D0 (en) Discovery
TH1501007139A (th) สารประกอบ 3,4-ไดไฮโดรไอโซควิโนลิน-2(1h)-อิล
TH160948B (th) สารประกอบ 3,4-ไดไฮโดรไอโซควิโนลิน-2(1h)-อิล
GB201321302D0 (en) Improved garment
GB201319736D0 (en) Improved Garment
GB201312705D0 (en) No access? button
AU2013902641A0 (en) Garment
AU2013900691A0 (en) Garment
GB201202989D0 (en) Wizz through 2 ceilings